All filters
Slidesets
Back-terial co-infections - Mohammed Lamorde, FRCP, PhD
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Specific Complex Interactions (mechanic presentation) - David Burger, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Real life cases - Elise Smolders
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
PBPK/PD Modeling and Simulations to Guide Dose Recommendation of Amlodipine after Co-administration with Viekirax or Viekira Pak - Dwaipayan Mukherjee, PhD
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Backing up clinical data with modelling - Marco Siccardi, PhD
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Effects of Sofosbuvir/Ribavirin Treatment and ITPA Phenotype on Endogenous Purines - Dr. Leah Jimmerson
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Rifampin (RIF) Decreases Cabotegravir (CAB) Exposure following Oral Coadministration - Dr. Susan Ford
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Increased Tenofovir Diphosphate in Red Blood Cells, but Not Tenofovir in Plasma, with Sofosbuvir and Ribavirin - Dr. Christine MacBrayne
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
MK-3682, a HCV NS5B Inhibitor with a Broad Spectrum of HCV Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotypes -1,-2, and -3 HCV-Infected Patients - Dr. Nancy Kim
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Pharmacokinetics of Darunavir, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir and Ribavirin in Adults Infected with Hepatitis C Virus (HCV) Genotype (GT) 1 and Human Immunodeficiency Virus Type 1 (HIV-1) - Dr. Jennifer King
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Physiologically-based simulation of daclatasvir pharmacokinetics with antiretroviral inducers and inhibitors of cytochrome P450 and drug transporters - Dr. Timothy Eley
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Pharmacokinetics of Dolutegravir after Switching to Abacavir/Dolutegravir/Lamivudine from an Efavirenz Based Regimen: A PK Substudy from Striiving - Dr. Jeff de Wet
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
A Clinically Meaningful Drug-Drug Interaction Observed Between ZepatierTM (Grazoprevir/Elbasvir) and Stribild® HIV Fixed-Dose Combination in Healthy Subjects - Dr. Hwa-Ping Feng
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
Evaluation of Pan Genotypic HCV NS3/4A Protease Inhibitor GS-9857 as the Object of Transporter and Cytochrome P450-Mediated Drug-Drug Interactions - Dr. Brian Kirby
Presented at:
International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016
Slidesets
(Abstract) Antiviral Activity of Tenofovir Alafenamide (TAF) against HIV-1 Subtypes and Emergence of K65R | Dr. C. Callebaut
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
(Abstract) Immunosuppression-driven HBV Reactivation in Patients with Resolved HBV Infection Correlates with a Relevant Risk of Evolution Towards Active Chronic Infection and Death | Dr. A. Battisti
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
(Abstract) Clinical impact of vaccine-escape HBsAg mutants in HBV-infected patients: high rate of atypical serological profiles and increased level of viremia and transaminases | Dr. R. Salpini
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
(Abstract) HBsAg immune-escape Mutations and Stop-Codons, Circulating among European HBV-chronically infected patients can impact on HBV transmission and disease progression | Dr. L. Colagrossi
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
Community perspective | Rebekah Webb
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
Roadblocks to implementation | Pep Coll, MD
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
Maintenance Therapy - What is the scientific/ virological rational | Charles Boucher, MD, PhD
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
HIV attachment Inhibitors - Educational lecture in collaboration with ESAR | Thomas Klimkait, MD
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
PI remain important options for first line | Linos Vandekerckhove, MD, PhD
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
Improving PI drug resistance scores | Jens Verheyen, MD, PhD
Presented at:
European Meeting on HIV & Hepatitis 2016